Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;115:1051-1058
doi: 10.1161/CIRCULATIONAHA.106.675934
Free Article
This Article
Free upon publication Free Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lüscher, T. F.
Right arrow Articles by Virmani, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lüscher, T. F.
Right arrow Articles by Virmani, R.
Related Collections
Right arrow Acute coronary syndromes
Right arrow Acute myocardial infarction
Right arrow Arterial thrombosis
Right arrow Catheter-based coronary interventions: stents
Right arrow Pathophysiology
Right arrowRelated Article

(Circulation. 2007;115:1051-1058.)
© 2007 American Heart Association, Inc.


Special Report

Drug-Eluting Stent and Coronary Thrombosis

Biological Mechanisms and Clinical Implications

Thomas F. Lüscher, MD; Jan Steffel, MD; Franz R. Eberli, MD; Michael Joner, MD; Gaku Nakazawa, MD; Felix C. Tanner, MD; Renu Virmani, MD

From Cardiology (T.F.L., J.S., F.R.E., F.C.T.), Cardiovascular Center, University Hospital Zürich, Zürich, Switzerland; Cardiovascular Research (T.F.L., J.S., F.C.T.), Physiology Institute, and Center for Integrative Human Physiology (T.F.L., J.S., F.C.T.), University of Zürich, Zürich, Switzerland; and CVPath Institute, Inc (M.J., G.N., R.V.), International Registry of Pathology, Gaithersburg, Md.

Correspondence to Thomas F. Lüscher, MD, Department of Cardiology, University of Zurich, Rämistrasse 100, 8091 Zürich, Switzerland. E-mail cardiotfl{at}gmx.ch

Although rare, stent thrombosis remains a severe complication after stent implantation owing to its high morbidity and mortality. Since the introduction of drug-eluting stents (DES), most interventional centers have noted stent thrombosis up to 3 years after implantation, a complication rarely seen with bare-metal stents. Some data from large registries and meta-analyses of randomized trials indicate a higher risk for DES thrombosis, whereas others suggest an absence of such a risk. Several factors are associated with an increased risk of stent thrombosis, including the procedure itself (stent malapposition and/or underexpansion, number of implanted stents, stent length, persistent slow coronary blood flow, and dissections), patient and lesion characteristics, stent design, and premature cessation of antiplatelet drugs. Drugs released from DES exert distinct biological effects, such as activation of signal transduction pathways and inhibition of cell proliferation. As a result, although primarily aimed at preventing vascular smooth muscle cell proliferation and migration (ie, key factors in the development of restenosis), they also impair reendothelialization, which leads to delayed arterial healing, and induce tissue factor expression, which results in a prothrombogenic environment. In the same way, polymers used to load these drugs have been associated with DES thrombosis. Finally, DES impair endothelial function of the coronary artery distal to the stent, which potentially promotes the risk of ischemia and coronary occlusion. Although several reports raise the possibility of a substantially higher risk of stent thrombosis in DES, evidence remains inconclusive; as a consequence, both large-scale and long-term clinical trials, as well as further mechanistic studies, are needed. The present review focuses on the pathophysiological mechanisms and pathological findings of stent thrombosis in DES.


Key Words: stents • thrombosis • pathology • physiology • risk factors • arteries • myocardial infarction


Related Article:

Issue Highlights
Circulation 2007 115: 945. [Full Text]



This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
T. Chechi, S. Vecchio, G. Vittori, G. Giuliani, A. Lilli, G. Spaziani, L. Consoli, G. Baldereschi, G. G.L. Biondi-Zoccai, I. Sheiban, et al.
ST-segment elevation myocardial infarction due to early and late stent thrombosis a new group of high-risk patients.
J. Am. Coll. Cardiol., June 24, 2008; 51(25): 2396 - 2402.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The year in interventional cardiology.
J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2355 - 2369.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. S. Brar, J. Kim, S. K. Brar, R. Zadegan, M. Ree, I.-L. A. Liu, P. Mansukhani, V. Aharonian, R. Hyett, and A. Y.-J. Shen
Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions.
J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2220 - 2227.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. I. Hamilos, M. Ostojic, B. Beleslin, D. Sagic, L. Mangovski, S. Stojkovic, M. Nedeljkovic, D. Orlic, B. Milosavljevic, D. Topic, et al.
Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion.
J. Am. Coll. Cardiol., June 3, 2008; 51(22): 2123 - 2129.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Jabs, S. Gobel, P. Wenzel, A. L. Kleschyov, M. Hortmann, M. Oelze, A. Daiber, and T. Munzel
Sirolimus-induced vascular dysfunction increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase-dependent superoxide production and decreased vascular nitric oxide formation.
J. Am. Coll. Cardiol., June 3, 2008; 51(22): 2130 - 2138.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. B. Muhlestein
Endothelial dysfunction associated with drug-eluting stents what, where, when, and how?
J. Am. Coll. Cardiol., June 3, 2008; 51(22): 2139 - 2140.
[Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
M. H. Shishehbor, R. Amini, L. P.J. Oliveria, I. M. Singh, P. Kelly, D. L. Bhatt, S. R. Kapadia, S. G. Ellis, P. L. Whitlow, and S. J. Brener
Comparison of Drug-Eluting Stents Versus Bare-Metal Stents for Treating ST-Segment Elevation Myocardial Infarction
J. Am. Coll. Cardiol. Intv., June 1, 2008; 1(3): 227 - 232.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. Filipe, L. Lam Shang Leen, L. Brouchet, A. Billon, V. Benouaich, V. Fontaine, P. Gourdy, F. Lenfant, J.-F. Arnal, A.-P. Gadeau, et al.
Estradiol accelerates endothelial healing through the retrograde commitment of uninjured endothelium
Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2822 - H2830.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
Y. Suzuki, F. Ikeno, T. Koizumi, F. Tio, A. C. Yeung, P. G. Yock, P. J. Fitzgerald, and W. F. Fearon
In Vivo Comparison Between Optical Coherence Tomography and Intravascular Ultrasound for Detecting Small Degrees of In-Stent Neointima After Stent Implantation
J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 168 - 173.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
D. P. Taggart
Does prior PCI increase the risk of subsequent CABG?
Eur. Heart J., March 1, 2008; 29(5): 573 - 575.
[Full Text] [PDF]


Home page
Therapeutic Advances in Cardiovascular DiseaseHome page
F. Saia, A. Marzocchi, and A. Branzi
Review: The safety of drug-eluting stents
Therapeutic Advances in Cardiovascular Disease, February 1, 2008; 2(1): 43 - 52.
[Abstract] [PDF]


Home page
J Am Coll Cardiol IntvHome page
J. Aoki, A. Kirtane, M. B. Leon, and G. Dangas
Coronary Artery Aneurysms After Drug-Eluting Stent Implantation
J. Am. Coll. Cardiol. Intv., February 1, 2008; 1(1): 14 - 21.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
American College of Cardiology/American Heart Asso, 2007 Writing Group to Review New Evidence and Upda, S. B. King III, S. C. Smith Jr, J. W. Hirshfeld Jr, A. K. Jacobs, D. A. Morrison, and D. O. Williams
2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention
J. Am. Coll. Cardiol., January 15, 2008; 51(2): 172 - 209.
[Full Text] [PDF]


Home page
CirculationHome page
S. B. King III, S. C. Smith Jr, J. W. Hirshfeld Jr, A. K. Jacobs, D. A. Morrison, D. O. Williams, 2005 WRITING COMMITTEE MEMBERS, S. C. Smith Jr, T. E. Feldman, J. W. Hirshfeld Jr, et al.
2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee
Circulation, January 15, 2008; 117(2): 261 - 295.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
K. Egashira, K. Nakano, K. Ohtani, K. Funakoshi, G. Zhao, Y. Ihara, J.-i. Koga, S. Kimura, R. Tominaga, and K. Sunagawa
Local Delivery of Anti-Monocyte Chemoattractant Protein-1 by Gene-Eluting Stents Attenuates In-Stent Stenosis in Rabbits and Monkeys
Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2563 - 2568.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A. Kastrati, A. Dibra, C. Spaulding, G. J. Laarman, M. Menichelli, M. Valgimigli, E. Di Lorenzo, C. Kaiser, I. Tierala, J. Mehilli, et al.
Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction
Eur. Heart J., November 2, 2007; 28(22): 2706 - 2713.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al.
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. Jaffe and B. H. Strauss
Late and Very Late Thrombosis of Drug-Eluting Stents: Evolving Concepts and Perspectives
J. Am. Coll. Cardiol., July 10, 2007; 50(2): 119 - 127.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
S. A. Spinler and R. L. Wilensky
Duration of clopidogrel therapy after placement of drug-eluting intracoronary stent
Am. J. Health Syst. Pharm., July 1, 2007; 64(13): 1432 - 1434.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. V. Finn, G. Nakazawa, M. Joner, F. D. Kolodgie, E. K. Mont, H. K. Gold, and R. Virmani
Vascular Responses to Drug Eluting Stents: Importance of Delayed Healing
Arterioscler. Thromb. Vasc. Biol., July 1, 2007; 27(7): 1500 - 1510.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
T. Matsumoto and P. M. Hwang
Resizing the Genomic Regulation of Restenosis
Circ. Res., June 8, 2007; 100(11): 1537 - 1539.
[Full Text] [PDF]


Home page
CirculationHome page
G. S. Mintz
What to Do About Late Incomplete Stent Apposition?
Circulation, May 8, 2007; 115(18): 2379 - 2381.
[Full Text] [PDF]